Hepatitis C - MIGENIX to Participate in "Breakthroughs in Hepatitis" Focus Session at the BIO CEO & Investor Conference in New York

MIGENIX to Participate in "Breakthroughs in Hepatitis" Focus Session at the BIO CEO & Investor Conference in New York
[Press Release] PR Newswire via Yahoo! Finance - Feb 13 10:26 AM
MIGENIX Inc. , a clinical-stage developer of drugs for infectious and degenerative diseases, has been selected to participate in the "Breakthroughs in Hepatitis" focus session at the 8th Annual BIO CEO & Investor Conference in New York City, February 14th and 15th.Save to My Web

YOU ARE HERE:
Aidsmap - Feb 17 4:51 AM
Virological response to hepatitis C therapy after four weeks appears to predict who will have a successful response to a full course of treatment in HIV-positive people coinfected with hepatitis C genotypes 1 or 3, according to findings from two studies presented last week at the Thirteenth Conference on Retroviruses and Opportunistic Infections in Denver.Save to My Web

Coley Pharmaceutical Group Initiates Phase II Clinical Study of Actilon(TM) for Hepatitis C
[Press Release] PR Newswire via Yahoo! Finance - Feb 23 5:30 AM
Coley Pharmaceutical Group, Inc. today announced the initiation of a randomized Phase II clinical study of Actilon for the treatment of patients with chronic Hepatitis C infection.Save to My Web

FDA Grants Fast Track Designation To Oral HCV Protease Inhibitor SCH 503034, Schering-Plough Reports
Medical News Today - Jan 30 4:21 PM
Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational oral hepatitis C protease inhibitor (SCH 503034), currently in Phase II clinical development for the treatment of chronic hepatitis C virus (HCV) infection. The FDA granted Fast Track designation for the following reasons: The proposed first indication for SCH Save to My Web